SUBSCRIBE
SUBSCRIBE

Lymphoma

FDA signage at its office in Maryland
FDA
BeiGene Secures Fifth Approval for Brukinsa, Expands into Follicular Lymphoma
BeiGene’s Brukinsa becomes the first BTK inhibitor approved for follicular lymphoma, the most common type of low-grade non-Hodgkin lymphoma.
March 8, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
PRESS RELEASES
Press Releases
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
October 16, 2025
 · 
4 min read
Press Releases
Arima Genomics Announces New Study Showing Aventa™ Lymphoma Test Resolves Diagnostic Ambiguity and Guides Care in B-Cell Lymphoma Cases
October 16, 2025
 · 
3 min read
Press Releases
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
October 15, 2025
 · 
18 min read
Press Releases
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
October 15, 2025
 · 
8 min read
Press Releases
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
October 13, 2025
 · 
7 min read
Press Releases
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
October 8, 2025
 · 
16 min read
Press Releases
Kernal Bio Awarded up to $48 Million from ARPA-H to Develop Lower Cost in vivo CAR T-cell Therapies for Hematological Cancers and Autoimmune Disease
October 7, 2025
 · 
4 min read
Press Releases
Verismo Therapeutics Treats First Follicular Lymphoma Patient in CELESTIAL-301 Trial, Strengthening Collaboration with IFLI
October 3, 2025
 · 
5 min read
Press Releases
Umoja Biopharma Announces that UB-VV111 Receives FDA Fast Track Designation for Relapsed/Refractory B-Cell Malignancies
October 1, 2025
 · 
2 min read
Press Releases
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
October 1, 2025
 · 
18 min read
Press Releases
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
October 1, 2025
 · 
5 min read
Press Releases
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
September 22, 2025
 · 
8 min read
Press Releases
Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
September 15, 2025
 · 
4 min read
Press Releases
Lilly’s Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL
September 8, 2025
 · 
16 min read
Press Releases
Huadong Medicine Announces Positive Preliminary Results from a Phase Ⅰ study of HDM2005, a ROR1-Targeting ADC
September 8, 2025
 · 
3 min read
Press Releases
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
September 8, 2025
 · 
2 min read
Press Releases
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
September 4, 2025
 · 
9 min read
Press Releases
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
September 4, 2025
 · 
15 min read
Press Releases
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
September 4, 2025
 · 
14 min read
Press Releases
Step Pharma announces first participant dosed in a phase 1b clinical trial of dencatistat for essential thrombocythaemia
September 3, 2025
 · 
4 min read
Load More